Inhibitors of phosphatidylinositol-3-kinase (PI3) and inducers of nitric oxide (NO)

A pharmaceutical composition comprising a compound of general formula 1:

• wherein
• R1 is one of H or COCH3, and
• R2 is one of H or COCH3,
• or R1 and R2 to combine to form —CH2—;
• R3 is one of H or CH2—CH═CH2, and
• R4 is one of H, CH2—CH═CH2, CH2—CH2—CH3, C(CH3)2CH═NOH , C(CH3)2CH═CH2, C(CH3)2CN, or C(CH3)2CH═NOCOCH3,
• wherein in the case that R3 is H, then R4 is CH2—CH2—CH3, C(CH3)2CH═NOH, C(CH3)2CH═CH2, C(CH3)2CN or C(CH3)2CH═NOCOCH3, and
• R5═H or CH2—CH═CH2;
• R6═H or CH2—CH═CH2;
• wherein
• in the case that R1 and R2 combine to form —CH3—, then R4 is C(CH3)2CH═CH2;
• and
• in the case that R3 and R2 are each H, then R4 is one of C(CH3)2CH═NOH, C(CH3)2CN or CH2—CH2—CH3,
• wherein the concentration of the compound is 0.1 to 99% by weight in a tablet or capsule;
• or 3-50% by volume are in a liquid preparation, along with pharmaceutically acceptable additive (s) or excipeint (s).

A pharmaceutical composition comprisiong a compound selected from the group consisting of:

• (E)-ethyl 4-(3,4-dihydroxyphenyl)-4-methylpent-2-encate;
• and
• (E)-4-(5-ethoxy-2-methyl-5-oxopent-3-en-2-yl)-1,2-phenylene diacetate,
• wherein the concentration of the compound is 0.1 to 99% by weight in a tablet or capsule;
• or 3-50% by volume are in a liquid preparation along with pharmaceutically acceptable additive(s) or excipient(s).